Table 2.
HIV-related characteristics at admission.
| Variables | Statistic value |
|---|---|
| Receiving ART (n, %) | 38 (79.2%) |
| ∗ time since ART initiation (years, median, and IQR) | 4 (2–9) |
| History of opportunistic infections (n, %) | 9 (18.8%) |
| Syphilis (n, %) | 16 (33.3%) |
| HCV (n, %) | 3 (6.3%) |
| ∗∗ CD4 cell counts before ACS (cells/μl, median, and IQR) | 365 (182–631) |
| ∗∗∗ VL before ACS (copies/ml, median, and IQR) | <40 (<40–37633) |
|
| |
| aART drugs (n, %) | |
| NRTIs | 18 (47.4%) |
| NNRTIs | 12 (31.6%) |
| PIs | 6 (15.8%) |
| Unknown | 2 (5.3%) |
The symbol ∗indicates that 38 patients were included receiving ART; the symbol ∗∗ indicates that the CD4 cell count was only available in 31 patients; the symbol ∗∗∗ indicates thatVL was only available in 26 patients. ART: antiretroviral therapy; IQR: interquartile range; HCV: hepatitis C virus; ACS: acute coronary syndrome; VL: HIV load; NNRTIs: non-nucleoside reverse transcriptase inhibitors; NRTIs: nucleoside reverse transcriptase inhibitors; PIs: protease inhibitors.